Access
To read this story in full you will need to login or make a payment (see right).
Correspondence
Nature 446, 856 (19 April 2007) | doi:10.1038/446856b; Published online 18 April 2007
Open Innovation Challenges
- More Challenges
- Powered by:
nature jobs
Chief Scientific Manager - Medicinal Chemistry
- Syngene International
- Bangalore, Karnataka 560099 India
Research Fellow
- Beth Israel Deaconess Medical Center
- Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215
Law and research could add up to profitable niche drugs
Burkhard Haefner1
- Johnson & Johnson Pharma Research and Development, Turnhoutseweg 30, Box 6423, 2340 Beerse, Belgium
In response to your Editorial "A changing drug supply" (Nature 445, 460; 2007), W. Ross Tracey points out in Correspondence that niche drugs may be just as expensive as blockbuster drugs to bring to the market, but a pharmaceutical company's revenue from them is likely to be only a fraction of what it can earn from selling blockbusters ("Niche drugs aren't a cheap alternative to blockbusters" Nature 445, 818; doi:10.1038/445818c 2007
To read this story in full you will need to login or make a payment (see right).
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
Niche drugs aren't a cheap alternative to blockbustersNature Correspondence (22 Feb 2007)
Challenges in Developing Therapies for Rare Diseases Including Pachyonychia CongenitaJournal of Investigative Dermatology Symposium Proceedings Original Article
